Investigation for efficacy and safety of tau PET ligand [18F]PM-PBB3 - Investigation for efficacy and safety of tau PET ligand [18F]PM-PBB3

ational Institute of Radiological Sciences0 个研究点目标入组 20 人开始时间: 2017年3月13日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Subjects who show obviously abnormal blood data at 1st day of the study 2. Subjects with organic brain complications/disorders (including a history of traumatic brain injury with loss of consciousness and/or hospital treatment, symptomatic cerebral infarction or hemorrhage) 3. Patients with substance-related disorders (including drug abuse) 4. Subjects with severe physical complications/disorders or a history of such conditions and who are considered to be inappropriate for participation by the aforementioned doctors with responsibilities in this study 5. Subjects with a pacemaker or other metallic medical device in the body (brain clip, bolts, etc.) 6. Subjects with tattoos 7. Subjects with claustrophobia 8. Pregnant, possibly pregnant or lactating women 9. From the standpoint of radiation exposure from a nuclear medicine scan, subjects who have participated in other nuclear medicine scans as healthy volunteers in the 12 months prior to the start of this study 10. Subjects who are considered to be inappropriate for participation by doctors with responsibilities in this study

发起方

ational Institute of Radiological Sciences